Worth A Second Look? Violin Memory Inc (VMEM), Apigee Corp (APIC) and Pernix Therapeutics Holdings Inc (PTX)

Posted by admin May 18, 2015 0 Comment 1137 views

New York, NY – GDP INSIDER  –  05/18/2014.

This article discusses three companies: Violin Memory Inc (NYSE:VMEM), Apigee Corp (NASDAQ:APIC) and Pernix Therapeutics Holdings Inc (NASDAQ:PTX)

Violin Memory Inc (NYSE:VMEM) continued to decline on Friday as the stock lost nine cents to finish the day at a closing price of $3.31, a 2.65% decline in value from its previous closing price on higher than average trading volume of 0.987 million, compared with its three month average trading volume of 0.876 million. The scalable memory appliances and technology provider has been underperforming the S&P 500 since the beginning of this year, with the stock down over 30%, compared to the index which is up 3.12% for the same period. However, with RSI of 39.80 and one year price target of $6.00, there is still plenty of long term potential so better to hold for now.

Is There Long Term Potential In Violin Memory Inc? Get A Free VMEM Investment Analysis Here.

Apigee Corp (NASDAQ:APIC) enjoyed a gain of 8.49% during Friday’s trading as the stock gained $1.16 to finish the day at a closing price of $14.82 on lower than average trading volume of 0.220 million, compared to its three month average trading volume of 0.644 million. Despite the gain, API based software platform provider is trading 27.71% below its one year high of $20.50. With the stock now underperforming the S&P 500 with a loss of 11 % YTD, versus the S&P 500 index which has increased over 3% for the period, it is a hold rather than a buy for now.

Can Apigee Corp Make Further Gains? Click Here For Free APIC Analysis.

Pernix Therapeutics Holdings Inc (NASDAQ:PTX) reversed its recent decline on Friday with the stock closing up 5.73% or $0.37 to finish the day at $6.83. The pharmaceutical company saw its volume spiked to a figure of 4.453 million shares, which is significantly higher than its three month average trading volume of 1.13 million, following the announcement of approval of its migraine drug, TREXIMET, by U.S. Food and Drug Administration. The stock has not been doing with the stock underperforming, down over 28% compared to 3.12% increase in S&P 500 for the period. With its MACD diverging in a bullish direction and a one year target price estimate of $13.30, there is still plenty of upside potential in the stock making it a good hold and potential medium to long term buy.

Are Pernix Therapeutics Holdings Inc Shares Undervalued? Examine the Potential With Free PTX Analysis.

About Ultimate Stock Alerts

UltimateStockAlerts.com covers NASDAQ and NYSE listed companies that are overlooked by Wall Street. Investors can choose to receive trading strategies via text message (SMS) or email. To receive free text message alerts text the word ULTIMATE to 555888 from your cell phone. For more information visit www.UltimateStockAlerts.com

Disclosure:  UltimateStockAlerts.com is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.

Write Your Comment